{
  "docId": "019de075-1362-766d-ac60-1333cab868aa",
  "docSlug": "7fe2865adefd4e627357f5c080658aba",
  "documentTitle": "Alkermes | Investor Presentation Deck | 56 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 56,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "other",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a hub-and-spoke diagram to show the core Alkermes business and a separate branch for the oncology spin-off.",
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de075-1362-766d-ac60-1333cab868aa/25",
  "deckHref": "/decks/019de075-1362-766d-ac60-1333cab868aa",
  "deckJsonHref": "/decks/019de075-1362-766d-ac60-1333cab868aa.json",
  "deckAnchorHref": "/decks/019de075-1362-766d-ac60-1333cab868aa#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.73,
        "y": 0.58
      },
      "kind": "callout",
      "text": "Separation anticipated H2 2023; Submitted confidential Form 10; Appointed Caroline J. Loew, Ph.D. as CEO",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1f5d13f2-0e3c-42ad-82c7-4ba97067fb3d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.9,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "diagram",
      "text": "Alkermes hub with spokes for commercial products, infrastructure, manufacturing, and R&D, plus a separate oncology branch.",
      "attrs": null,
      "subkind": "hub-spoke",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d0939393-bc8a-4b31-bdd5-73b64ea93426",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "1 VUMERITY is licensed to and commercialized exclusively by Biogen. 2 Assuming separation of the company's oncology business is effected through a spin-off of the oncology business into an independent, publicly-traded company.",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fc077b67-63c0-4779-b742-0d36b686f75b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Separating the Alkermes Oncology Business Expected to Yield Value for Shareholders",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2fe21cc0-27ae-42fe-8b10-78c8a65b3a51",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "breakup-spinoff",
      "slug": null,
      "matchId": "1e03f08f-7d49-4650-a678-1a2c91aed3bd",
      "evidence": "The slide describes the separation of the oncology business into an independent company.",
      "confidence": 0.95
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}